Tildacerfont - Spruce Biosciences
Alternative Names: SPR 001Latest Information Update: 10 Jun 2024
At a glance
- Originator Spruce Biosciences
- Class 2 ring heterocyclic compounds; Morpholines; Pyrazoles; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Congenital adrenal hyperplasia; Polycystic ovary syndrome
Most Recent Events
- 04 Jun 2024 Spruce Biosciences and HMNC Brain Health entered into a strategic collaboration agreement to develop tildacerfont for major depressive disorder
- 04 Jun 2024 Spruce Biosciences in collaboration with HMNC Brain Health plans a phase II proof-of-concept study of tildacerfont and Cortibon for Major depressive disorder in 2024
- 03 Jun 2024 Efficacy and adverse event data from the phase II P.O.W.E.R trial in Polycystic ovary syndrome released by Spruce Biosciences